Vertex Pharmaceuticals, Inc. (VRTX)
|Net Income (ttm)||2.76B|
|Trading Day||May 10|
|Day's Range||213.54 - 216.28|
|52-Week Range||202.57 - 306.08|
If the growth stock sell-off accelerates, this Fool will be looking to open a position in each of these innovative companies.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $215.01, marking a +0.87% move from the previous day.
The cystic fibrosis specialist is moving into other lucrative areas.
Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.
Make every dollar count.
The biotech's improving fortunes relied on one drug.
Don't count these ARK Invest ETF holdings out.
Vertex (VRTX) delivered earnings and revenue surprises of 7.58% and 3.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 16.41% over the past year to $2.98, which bea...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2021 and reiterated full-year 2021 guidanc...
Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Iva...
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KAFTRIO® (ivacaftor/tezacaftor/el...
On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective NaV1.8 inhibitor, VX-548, into Phase 2 clinical development with clinical t...
They're generating revenue now -- and more is on the way.
See if the formerly high-flying biotech deserves a place in your portfolio.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Privately-held Obsidian Therapeutics have entered into a research collaboration and licensing agreement to discover novel therapies that regulate g...
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex and Obsidian Therapeutics announced a strategic research collaboration and licensing agreement for novel therapies to regulate gene editing.
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $220.16, marking a +0.45% move from the previous day.
Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important upda...
The amended collaboration agreement comes with a big up-front payment.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The compan...
Bargains abound if you're shopping for high-quality growth stocks.
They're among the top 10 holdings in one of Ark Invest's biggest funds.
And they all have one key thing in common.
We believe that the stock price of Vertex Pharmaceuticals is undervalued at current levels of $215. VRTX stock is up a mere 6% off the March 2020 bottom compared to the S&P which moved 85%.
These companies are big-time bargains in the eyes of professional investors.
Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.
Value stocks are historically the place to be when the U.S. economy is rebounding from a recession.
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor t...
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a pos...
Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat Peopl...
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of TRIKAFTA® (elexacaftor/teza...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $211.54, moving -0.96% from the previous trading session.
They're leaders in their niche markets. And they have great growth prospects.
Once the market's dust settles, these two successful companies will continue winning.
These innovative stocks have the potential to skyrocket under the new administration.
Vertex Pharmaceuticals (VRTX) closed at $215.15 in the latest trading session, marking a +0.4% move from the prior day.
Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investig...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the co...
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
These high-growth stocks should handily outperform the most-popular Reddit rally companies.
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
These fast-paced businesses can supercharge investors' portfolios.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitr... [Read more...]
|IPO Date |
Jul 24, 1991
|Stock Exchange |
|Ticker Symbol |
In 2020, VRTX's revenue was $6.21 billion, an increase of 49.07% compared to the previous year's $4.16 billion. Earnings were $2.71 billion, an increase of 130.42%.
According to 28 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 284.68, which is an increase of 33.31% from the latest price.